30 news items
KRAZATI (adagrasib) Demonstrated Statistically Significant Improvement in Progression-Free Survival in Patients with Pretreated Locally Advanced or Metastatic KRASG12C-Mutated Non-Small Cell Lung Cancer
BMY
1 Jun 24
of cancer deaths globally. The two main types of lung cancer are non-small cell and small cell. Non-small cell lung cancer (NSCLC) is one of the most common
U.S. Food and Drug Administration Approves Bristol Myers Squibb's Breyanzi as a New CAR T Cell Therapy for Relapsed or Refractory Mantle Cell Lymphoma
BMY
30 May 24
with a median duration of 5 days (range: 1 to 37 days). One patient had fatal CRS and 5 patients had ongoing CRS at the time of death. The most common
Biotech Sector Working to Combat Rising Cases of Colorectal Cancer in Young Adults
BMY
CCCC
ONCY
28 May 24
of disease progression or death by 79% versus chemotherapy
Biotech Sector Working to Combat Rising Cases of Colorectal Cancer in Young Adults
BMY
CCCC
ONCY
28 May 24
of disease progression or death by 79% versus chemotherapy in patients
Bristol Myers Squibb to Present Data at ASCO & EHA from More Than 130 Studies Across 25 Diseases Supporting Expansion into New Indications, Demonstrating Long-Term Survival, and Highlighting Novel Modalities and Research Platforms
BMY
23 May 24
(1.0%), septic shock (0.5%), esophageal fistula (0.5%), gastrointestinal hemorrhage (0.5%), pulmonary embolism (0.5%), and sudden death (0.5
octd goh9b1z5tqsv49gqcczycb
BMY
16 May 24
, 0.9), major adverse cardiovascular events (Year 1, 0.3; Year 4, 0.3), venous thromboembolism (Year 1, 0.2; Year 4, 0.1) and deaths (Year 1, 0.2; Year
9de j2cndjfcxw
BMY
15 May 24
reactivation: Hepatitis B virus (HBV) reactivation, in some cases resulting in fulminant hepatitis, hepatic failure, and death, can occur in patients
15e89 ar36b7u
BMY
10 May 24
Lung cancer is the leading cause of cancer deaths globally. Non-small cell lung cancer (NSCLC) is one of the most
b57rs9
BMY
26 Apr 24
of death by 22%, demonstrating a median OS of 21.7 months versus 18.9 months with cisplatin-gemcitabine alone (Hazard Ratio [HR] 0.78; 95% Confidence
vmcynjktk6gccr34 12m5k2l
BMY
12 Apr 24
Bristol Myers's CAR-T cell therapy Abecma. The briefing documents noted that Abecma was linked to earlier deaths, citing late-stage clinical trial
abbefu
BMY
JNJ
MRK
10 Apr 24
and this time round, they are turning to the world’s most common causes of death- cancer and heart disease.
Johnson & Johnson
lc0 os3jq8p
BMY
8 Apr 24
CAR-T cell therapy Abecma. The briefing documents noted that Abecma was linked to earlier deaths, citing late-stage clinical trial data submitted
hvshs25a
BMY
8 Apr 24
for ventricular tachyarrhythmias (e.g., torsades de pointes) or sudden death
In the pooled safety
4m7pekqkjxe xfxt3dbsbzb0cu57eu70v3haahnv02f59qvdotz9esr
BMY
TSVT
5 Apr 24
in the Phase 3 KarMMa-3 trial, with a 51% reduction in risk of disease progression or death and a well-established safety profile
899w1djc35ihsolxfunqbpyasud9zz76i v4iz1bu
BMY
TSVT
5 Apr 24
in the Phase 3 KarMMa-3 trial, with a 51% reduction in risk of disease progression or death and a well-established safety profile
0o8ioo2uzjz6ronncz
BMY
4 Apr 24
Bristol Myers's CAR-T cell therapy Abecma. The briefing documents noted that Abecma was linked to earlier deaths, citing late-stage clinical trial
dymb73yvsvb0kfxpoxjwkjcniac1b bd9y
BMY
2 Apr 24
).
Safety results were consistent with previous MDS studies, and progression to acute myeloid leukemia and total deaths were
7wfoam52kq300g60mxz xr
BMY
31 Mar 24
, regarding Bristol Myers's CAR-T cell therapy Abecma. The briefing documents noted that Abecma was linked to earlier deaths, citing late-stage clinical trial
ksxs2lg0er r7t7xmw7v6cx
BMY
27 Mar 24
Bristol Myers's CAR-T cell therapy Abecma. The briefing documents noted that Abecma was linked to earlier deaths, citing late-stage clinical trial
t9h7pkipt3x7hp7jt61g3xvvf1s1z321bqgw615i9u
BMY
MRK
27 Mar 24
improved multiple secondary outcome measures, including reducing the risk of death from any cause or PAH clinical worsening events by 84% versus